© 2021 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
February 7th 2013
Peter A. Kaufman, MD, Associate Professor of Medicine at the Geisel School of Medicine at Dartmouth, discusses the side effect profiles of the microtubule inhibitor eribulin mesylate and the oral chemotherapeutic agent capecitabine.